| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
About This CME Activity
|
|
|
2010
|
|
2 |
p. 58-
1 p.
|
artikel
|
| 2 |
A community oncologist comments
|
Bosserman, Linda D.
|
|
2004
|
|
2 |
p. 87-91
5 p.
|
artikel
|
| 3 |
A cornerstone of hematological science
|
Yavorkovsky, Leonid L.
|
|
2012
|
|
2 |
p. 65-
1 p.
|
artikel
|
| 4 |
A crystal ball for 2008
|
Okon, Ted
|
|
2008
|
|
2 |
p. 105-106
2 p.
|
artikel
|
| 5 |
Advances in breast cancer treatment
|
|
|
2006
|
|
2 |
p. 86-
1 p.
|
artikel
|
| 6 |
Advances in multiple myeloma treatment: lenalidomide and bortezomib
|
Abraham, Jame
|
|
2009
|
|
2 |
p. 53-55
3 p.
|
artikel
|
| 7 |
Ampullary cancer: review and clinical update
|
Chan, Melissa
|
|
2010
|
|
2 |
p. 61-66
6 p.
|
artikel
|
| 8 |
Angioimmunoblastic T-cell lymphoma presenting as extensive psoriasis: a case report and discussion
|
Zaiden, Robert
|
|
2010
|
|
2 |
p. 90-92
3 p.
|
artikel
|
| 9 |
Anxiety in high-risk or already diagnosed cancer patients: recognizing and treating external and internal sources
|
Carter, Susan
|
|
2008
|
|
2 |
p. 113-
1 p.
|
artikel
|
| 10 |
A reflection of progress and hope
|
Rosenfeld, Myrna R.
|
|
2006
|
|
2 |
p. 116-
1 p.
|
artikel
|
| 11 |
Ask your lawyer
|
Doty, Lee W.
|
|
2006
|
|
2 |
p. 114-115
2 p.
|
artikel
|
| 12 |
A step forward in targeted treatment for breast cancer
|
Mallidi, Padmaja V.
|
|
2007
|
|
2 |
p. 75-77
3 p.
|
artikel
|
| 13 |
A 72-year-old man with a large, left-upper-lobe lung mass
|
Danso, Michael A.
|
|
2008
|
|
2 |
p. 93-94
2 p.
|
artikel
|
| 14 |
Bevacizumab-related toxicities: association of hypertension and proteinuria
|
Martel, Cynthia L.
|
|
2006
|
|
2 |
p. 90-93
4 p.
|
artikel
|
| 15 |
Bortezomib in multiple myeloma
|
|
|
2004
|
|
2 |
p. 77-79
3 p.
|
artikel
|
| 16 |
Brachytherapy for prostate cancer
|
Terk, Mitchell D.
|
|
2007
|
|
2 |
p. 89-92
4 p.
|
artikel
|
| 17 |
Breaking bad news: the S-P-I-K-E-S strategy
|
Buckman, Robert A.
|
|
2005
|
|
2 |
p. 138-142
5 p.
|
artikel
|
| 18 |
Breast cancer presenting in aberrant axillary breast tissue
|
Bakker, Jennifer R.
|
|
2005
|
|
2 |
p. 117-120
4 p.
|
artikel
|
| 19 |
Bringing cancer care to people, where they live
|
Vanchieri, Cori
|
|
2008
|
|
2 |
p. 75-76
2 p.
|
artikel
|
| 20 |
Building a patient-focused office culture
|
Young, Patrick
|
|
2009
|
|
2 |
p. 86-88
3 p.
|
artikel
|
| 21 |
Cancer Care Act of 2004 introduced in the Senate
|
|
|
2004
|
|
2 |
p. 124-
1 p.
|
artikel
|
| 22 |
Cancer genetic counseling in rural North Carolina oncology clinics: program establishment and patient characteristics
|
Buchanan, Adam H.
|
|
2009
|
|
2 |
p. 70-77
8 p.
|
artikel
|
| 23 |
Cancer genetics, Medicare maze, and more…
|
Henry, David H.
|
|
2006
|
|
2 |
p. 66-
1 p.
|
artikel
|
| 24 |
Can community-based oncology practices (or patients) afford lapatinib?
|
Dozier, Nicky
|
|
2007
|
|
2 |
p. 78-
1 p.
|
artikel
|
| 25 |
Choosing treatment options in newly diagnosed patients with multiple myeloma
|
Neelapu, Sattva S.
|
|
2009
|
|
2 |
p. 55-
1 p.
|
artikel
|
| 26 |
Circulating tumor cells in the management of metastatic breast cancer patients
|
Beveridge, Roy
|
|
2007
|
|
2 |
p. 79-82
4 p.
|
artikel
|
| 27 |
Clinical research and clinical experience: a discussion
|
|
|
2007
|
|
2 |
p. 72-
1 p.
|
artikel
|
| 28 |
CML patients with imatinib-resistant mutations responsive to dasatinib and nilotinib
|
|
|
2007
|
|
2 |
p. 106-107
2 p.
|
artikel
|
| 29 |
Committees, explained
|
|
|
2007
|
|
2 |
p. 104-105
2 p.
|
artikel
|
| 30 |
Contents
|
|
|
2012
|
|
2 |
p. A6-
1 p.
|
artikel
|
| 31 |
Data-driven medical decision-making in managing chemotherapy-induced nausea and vomiting
|
Feinberg, Bruce A.
|
|
2009
|
|
2 |
p. 62-67
6 p.
|
artikel
|
| 32 |
Deciding on your Medicare prescription drug coverage
|
|
|
2006
|
|
2 |
p. 112-
1 p.
|
artikel
|
| 33 |
Denosumab in cancer patients with bone metastases
|
Abraham, Jame
|
|
2011
|
|
2 |
p. 59-61
3 p.
|
artikel
|
| 34 |
Developments in antiemetic therapy
|
|
|
2004
|
|
2 |
p. 79-81
3 p.
|
artikel
|
| 35 |
Dual HER1/HER2 inhibitor lapatinib in advanced/metastatic breast cancer
|
Abraham, Jame
|
|
2007
|
|
2 |
p. 73-75
3 p.
|
artikel
|
| 36 |
Ectopic breast cancer: rare, treatable, and potentially curable
|
Daniel, Brooke R.
|
|
2005
|
|
2 |
p. 120-122
3 p.
|
artikel
|
| 37 |
Eculizumab for paroxysmal nocturnal hemoglobinuria
|
Abraham, Jame
|
|
2008
|
|
2 |
p. 67-69
3 p.
|
artikel
|
| 38 |
Editorial Board
|
|
|
2012
|
|
2 |
p. A5-
1 p.
|
artikel
|
| 39 |
Effect of oncologist-based counseling on patient-perceived breast cancer risk and psychological distress
|
Mertens, Wilson C.
|
|
2008
|
|
2 |
p. 108-114
7 p.
|
artikel
|
| 40 |
Electronic medical records: taking the plunge
|
|
|
2005
|
|
2 |
p. 157-
1 p.
|
artikel
|
| 41 |
Evaluating needs and the integrated model
|
Stutzman, Susan Carter
|
|
2012
|
|
2 |
p. 73-74
2 p.
|
artikel
|
| 42 |
Experts predict more pressure to standardize, measure quality of cancer care
|
Kelly, Janis
|
|
2004
|
|
2 |
p. 103-104
2 p.
|
artikel
|
| 43 |
Extramammary Paget's disease
|
Rao, Venkatesh R.
|
|
2004
|
|
2 |
p. 109-114
6 p.
|
artikel
|
| 44 |
First-line treatment of chronic myeloid leukemia: imatinib versus nilotinib and dasatinib
|
DiBella, Nicholas J.
|
|
2011
|
|
2 |
p. 65-72
8 p.
|
artikel
|
| 45 |
Fitting bortezomib into clinical practice
|
Vescio, Robert A.
|
|
2004
|
|
2 |
p. 78-79
2 p.
|
artikel
|
| 46 |
Hereditary breast and ovarian cancer testing: integration and outcomes within community oncology practices
|
Eisenbraun, Ann
|
|
2010
|
|
2 |
p. 75-81
7 p.
|
artikel
|
| 47 |
Hereditary cancer: the challenges are pedigree interpretation, risk assessment, and management—not genetic testing
|
Fowler, Eric
|
|
2010
|
|
2 |
p. 82-83
2 p.
|
artikel
|
| 48 |
HMO profits soar, healthcare falters
|
|
|
2004
|
|
2 |
p. 119-120
2 p.
|
artikel
|
| 49 |
How we do it: acute antiemetic treatment
|
Maxwell, Cathy
|
|
2004
|
|
2 |
p. 82-
1 p.
|
artikel
|
| 50 |
Hypertension therapy for the oncology patient
|
Miles, J. Shawn
|
|
2006
|
|
2 |
p. 94-99
6 p.
|
artikel
|
| 51 |
I had a dream
|
Feinberg, Bruce A.
|
|
2005
|
|
2 |
p. 157-160
4 p.
|
artikel
|
| 52 |
iKnowMed: from rough road to smooth sailing
|
Henry, David H.
|
|
2005
|
|
2 |
p. 160-161
2 p.
|
artikel
|
| 53 |
Image-guided radiation therapy: techniques and strategies
|
Warlick, William B.
|
|
2008
|
|
2 |
p. 86-92
7 p.
|
artikel
|
| 54 |
IMPAC: oncology-specific, best-of-breed
|
Smith Jr., Robert E.
|
|
2005
|
|
2 |
p. 166-167
2 p.
|
artikel
|
| 55 |
Implications of improved survival in patients with chronic myeloid leukemia: a nursing perspective
|
Ault, Patricia S.
|
|
2012
|
|
2 |
p. 56-64
9 p.
|
artikel
|
| 56 |
Incidence of acute phase adverse events following denosumab or intravenous bisphosphonates: results from a randomized, controlled phase II study in patients with breast cancer and bone metastases
|
Campbell-Baird, Cynthia
|
|
2010
|
|
2 |
p. 85-89
5 p.
|
artikel
|
| 57 |
Intraperitoneal chemotherapy for ovarian cancer
|
Robinson, William R.
|
|
2010
|
|
2 |
p. 67-72
6 p.
|
artikel
|
| 58 |
IP chemotherapy for ovarian cancer: is the questionable benefit worth the added toxicity?
|
Chu, Christina S.
|
|
2010
|
|
2 |
p. 73-74
2 p.
|
artikel
|
| 59 |
Irinotecan pharmacogenetics: an overview for the community oncologist
|
Pangilinan, Joanna Maudlin
|
|
2008
|
|
2 |
p. 99-103
5 p.
|
artikel
|
| 60 |
Iron chelation therapy improves survival in MDS
|
|
|
2007
|
|
2 |
p. 108-109
2 p.
|
artikel
|
| 61 |
Iron or vitamin B12 deficiency in anemic cancer patients prior to erythropoiesis-stimulating agent therapy
|
Henry, David H.
|
|
2007
|
|
2 |
p. 95-101
7 p.
|
artikel
|
| 62 |
Ischemic myositis in a diabetic patient receiving chemotherapy
|
Vatca, Mihaela-Alina
|
|
2009
|
|
2 |
p. 69-
1 p.
|
artikel
|
| 63 |
Is oncology compatible with specialty pharmacy?
|
Holcombe, Dawn G.
|
|
2005
|
|
2 |
p. 173-181
9 p.
|
artikel
|
| 64 |
ITP in Patients Infected With Hepatitis C Virus: Practicing With Howard Liebman, MD
|
|
|
2010
|
|
2 |
p. 58-59
2 p.
|
artikel
|
| 65 |
It's time to rethink the rationale of the Medicare Hospice Benefit
|
Ponder-Stansel, Susan
|
|
2007
|
|
2 |
p. 67-68
2 p.
|
artikel
|
| 66 |
Ixabepilone in advanced breast cancer: clinical, treatment, and cost-related studies
|
Brufsky, Adam
|
|
2011
|
|
2 |
p. 73-80
8 p.
|
artikel
|
| 67 |
Joining forces to beat multiple myeloma
|
Nierengarten, Mary Beth
|
|
2006
|
|
2 |
p. 75-76
2 p.
|
artikel
|
| 68 |
Legal considerations in clinical cancer genetics
|
Anderson, Rebecca Rae
|
|
2006
|
|
2 |
p. 100-104
5 p.
|
artikel
|
| 69 |
Lenalidomide in myelodysplastic syndromes
|
Tucker, Steven J.
|
|
2006
|
|
2 |
p. 71-72
2 p.
|
artikel
|
| 70 |
Lessons learned
|
Marshall, John L.
|
|
2004
|
|
2 |
p. 114-
1 p.
|
artikel
|
| 71 |
Lobular carcinoma of the breast: a ‘sneaky’ cancer
|
Moore, Anne
|
|
2006
|
|
2 |
p. 107-109
3 p.
|
artikel
|
| 72 |
Long-term responses seen with rituximab in patients with ITP
|
|
|
2007
|
|
2 |
p. 107-
1 p.
|
artikel
|
| 73 |
Looking ahead to rational combinatorial therapy
|
Mittra, Arjun
|
|
2012
|
|
2 |
p. 40-41
2 p.
|
artikel
|
| 74 |
Male alopecia, finasteride, and cancer risk
|
Revannasiddaiah, Swaroop
|
|
2012
|
|
2 |
p. 65-66
2 p.
|
artikel
|
| 75 |
Management of capecitabine-related gastrointestinal toxicities in women with breast cancer
|
Bayraktar, Soley
|
|
2011
|
|
2 |
p. 81-87
7 p.
|
artikel
|
| 76 |
Managing the side effects of lenalidomide and bortezomib
|
Richards, Tiffany
|
|
2009
|
|
2 |
p. 56-57
2 p.
|
artikel
|
| 77 |
Mantle cell lymphoma of the prostate
|
Genkin, Igor
|
|
2006
|
|
2 |
p. 69-
1 p.
|
artikel
|
| 78 |
Mass screening: when does it make sense?
|
Streiner, David L.
|
|
2010
|
|
2 |
p. 93-95
3 p.
|
artikel
|
| 79 |
Maximizing clinical outcomes with axitinib therapy in advanced renal cell carcinoma through proactive side-effect management
|
Wood, Laura S.
|
|
2012
|
|
2 |
p. 46-55
10 p.
|
artikel
|
| 80 |
MDS patients with pretransplant neutropenia at risk for infections, higher mortality
|
|
|
2007
|
|
2 |
p. 109-110
2 p.
|
artikel
|
| 81 |
Medicare changes must be made now
|
Okon, Ted
|
|
2005
|
|
2 |
p. 187-188
2 p.
|
artikel
|
| 82 |
Medicare maze, Part D
|
Vanchieri, Cori
|
|
2006
|
|
2 |
p. 111-
1 p.
|
artikel
|
| 83 |
More options for patients with MDS
|
Piro, Lawrence D.
|
|
2006
|
|
2 |
p. 73-
1 p.
|
artikel
|
| 84 |
New antiresorptive agents in metastatic breast cancer: an advance or more of the same?
|
Brufsky, Adam
|
|
2011
|
|
2 |
p. 61-62
2 p.
|
artikel
|
| 85 |
Novel alternative for treating paroxysmal nocturnal hemoglobinuria in selected patients
|
Battiwalla, Minoo
|
|
2008
|
|
2 |
p. 70-
1 p.
|
artikel
|
| 86 |
Oncology and hospice care
|
Weissman, David E.
|
|
2004
|
|
2 |
p. 85-91
7 p.
|
artikel
|
| 87 |
Oncology EMR comes of age
|
Schwartzberg, Lee S.
|
|
2005
|
|
2 |
p. 107-
1 p.
|
artikel
|
| 88 |
One transition at a time, please
|
London, Susan
|
|
2011
|
|
2 |
p. 92-
1 p.
|
artikel
|
| 89 |
OpTx: essential for growth
|
Moore, Timothy D.
|
|
2005
|
|
2 |
p. 167-168
2 p.
|
artikel
|
| 90 |
Palliation of vasomotor instability (“hot flashes”) using pregabalin
|
Presant, Cary A.
|
|
2007
|
|
2 |
p. 83-84
2 p.
|
artikel
|
| 91 |
Pazopanib in advanced renal cell carcinoma
|
Abraham, Jame
|
|
2010
|
|
2 |
p. 56-57
2 p.
|
artikel
|
| 92 |
PDA applications: drug reference guides
|
|
|
2004
|
|
2 |
p. 105-107
3 p.
|
artikel
|
| 93 |
Pertuzumab plus trastuzumab and docetaxel in HER2-positive metastatic breast cancer
|
Abraham, Jame
|
|
2012
|
|
2 |
p. 42-44
3 p.
|
artikel
|
| 94 |
Podcasting: your information pipeline
|
Fried, John J.
|
|
2006
|
|
2 |
p. 113-
1 p.
|
artikel
|
| 95 |
Preventing chemotherapy-induced nausea and vomiting: the economic implications of choosing antiemetics
|
Vanscoy, Gordon J.
|
|
2005
|
|
2 |
p. 127-132
6 p.
|
artikel
|
| 96 |
Protecting your patient and yourself
|
Mackarey, Judith
|
|
2006
|
|
2 |
p. 104-
1 p.
|
artikel
|
| 97 |
RACs are a reality: what now?
|
|
|
2010
|
|
2 |
p. 96-
1 p.
|
artikel
|
| 98 |
Radiation overexposure following brain perfusion CT scans in California, Florida, and Alabama (2008–2009)
|
Qureshi, Zaina P.
|
|
2011
|
|
2 |
p. 89-91
3 p.
|
artikel
|
| 99 |
Randomized controlled trials
|
Streiner, David L.
|
|
2009
|
|
2 |
p. 83-85
3 p.
|
artikel
|
| 100 |
Real-world oncology in a political year
|
Henry, David H.
|
|
2008
|
|
2 |
p. 59-
1 p.
|
artikel
|
| 101 |
Research highlights for hematologic cancers
|
|
|
2006
|
|
2 |
p. 85-
1 p.
|
artikel
|
| 102 |
Rituximab plus CHOP improves outcomes in elderly with follicular lymphoma
|
|
|
2007
|
|
2 |
p. 108-
1 p.
|
artikel
|
| 103 |
Shortcomings and flaws in Medicare coding that affect oncologist practices
|
|
|
2004
|
|
2 |
p. 123-124
2 p.
|
artikel
|
| 104 |
Sildenafil- and tadalafil-associated optic neuropathy: implications for men after prostate cancer treatment
|
McKoy, June M.
|
|
2009
|
|
2 |
p. 78-79
2 p.
|
artikel
|
| 105 |
Specialty pharmacy and MVI: ill-advised systems, wasteful and harmful
|
Bosserman, Linda D.
|
|
2005
|
|
2 |
p. 178-180
3 p.
|
artikel
|
| 106 |
Staying on top of it all
|
Henry, David H.
|
|
2010
|
|
2 |
p. 55-
1 p.
|
artikel
|
| 107 |
Straight talk on alternative and complementary therapies
|
Vanchieri, Cori
|
|
2005
|
|
2 |
p. 145-149
5 p.
|
artikel
|
| 108 |
Synchronous presentation of advanced rectal and intermediate-risk prostate cancers: a multidisciplinary approach
|
Watkins, John M.
|
|
2012
|
|
2 |
p. 67-72
6 p.
|
artikel
|
| 109 |
Targeted therapies and expanding roles
|
Henry, David H.
|
|
2012
|
|
2 |
p. 35-
1 p.
|
artikel
|
| 110 |
Thalidomide—defining a role…finally
|
Tucker, Steve
|
|
2005
|
|
2 |
p. 113-115
3 p.
|
artikel
|
| 111 |
Thalidomide in multiple myeloma
|
|
|
2005
|
|
2 |
p. 111-113
3 p.
|
artikel
|
| 112 |
The baptism
|
Goldsmith, Myron
|
|
2005
|
|
2 |
p. 135-136
2 p.
|
artikel
|
| 113 |
The FDA's Avastin decision flies in the face of science-based medicine
|
Schwartzberg, Lee S.
|
|
2011
|
|
2 |
p. 57-
1 p.
|
artikel
|
| 114 |
The list of novel agents for advanced renal cell carcinoma expands yet again
|
Choueiri, Toni K.
|
|
2010
|
|
2 |
p. 57-
1 p.
|
artikel
|
| 115 |
The NCCN guidelines: how do they relate to community oncology practice?
|
Powers, Ellen Okin
|
|
2004
|
|
2 |
p. 98-102
5 p.
|
artikel
|
| 116 |
The role of lapatinib in the treatment of breast cancer
|
Tarpley, Trish
|
|
2007
|
|
2 |
p. 77-78
2 p.
|
artikel
|
| 117 |
Transitioning patients to palliative care
|
Schwartzberg, Lee S.
|
|
2004
|
|
2 |
p. 75-76
2 p.
|
artikel
|
| 118 |
Ultrasonography-guided assessment of surgical margins in oral carcinoma—a study of three cases
|
Prabhakaran, Sakthi Samyuktha
|
|
2008
|
|
2 |
p. 78-80
3 p.
|
artikel
|
| 119 |
Ultrasonography may hold promise for pre- and intraoperative evaluation of head and neck cancers
|
Holsinger, Christopher
|
|
2008
|
|
2 |
p. 80-81
2 p.
|
artikel
|
| 120 |
Vulvar metastasis from breast cancer
|
Mullai, N.
|
|
2006
|
|
2 |
p. 106-
1 p.
|
artikel
|
| 121 |
Web sites you can recommend to your patients
|
Fried, John J.
|
|
2009
|
|
2 |
p. 81-82
2 p.
|
artikel
|
| 122 |
What practitioners—and their patients—want to know
|
Henry, David H.
|
|
2007
|
|
2 |
p. 58-
1 p.
|
artikel
|
| 123 |
While we wait for the big fix…
|
Henry, David H.
|
|
2009
|
|
2 |
p. 50-
1 p.
|
artikel
|
| 124 |
Why Medicare expenditures for cancer drugs are under fire
|
Okon, Ted
|
|
2004
|
|
2 |
p. 123-
1 p.
|
artikel
|
| 125 |
Will partial breast irradiation be a cost-effective alternative to whole breast irradiation in the treatment of early-stage breast cancer?
|
Konski, Andre A.
|
|
2004
|
|
2 |
p. 93-97
5 p.
|
artikel
|
| 126 |
Your political action guide to Congress
|
Kruczynski, Mary
|
|
2007
|
|
2 |
p. 103-104
2 p.
|
artikel
|
Tijdschrift beschrijving